ライフサイエンスコーパス: risk of bleeding

1 rial fibrillation (score >/=3 indicates high risk of bleeding).

2 o a reduced rate of VTE without an increased risk of bleeding.

3 of post-ERCP pancreatitis without increasing risk of bleeding.

4 ding and 217 procedures (40%) with increased risk of bleeding.

5 therapy can be associated with an increased risk of bleeding.

6 ving the lesion by thoracotomy to reduce the risk of bleeding.

7 activity may aid in assessing the individual risk of bleeding.

8 myocardial infarction (MI) but increases the risk of bleeding.

9 and appeared to be safe with respect to the risk of bleeding.

10 >/= 10 mm Hg) and esophageal varices at high risk of bleeding.

11 oral obstruction, severe symptoms, and a low risk of bleeding.

12 ion-driven thrombosis without increasing the risk of bleeding.

13 o alterations in their efficacy and a higher risk of bleeding.

14 icoagulation in preventing stroke versus the risk of bleeding.

15 epsis in mouse models without increasing the risk of bleeding.

16 r 100 person-years, who are not at increased risk of bleeding.

17 efficacy to higher dose aspirin with reduced risk of bleeding.

18 ed VTE, without significantly increasing the risk of bleeding.

19 ually stopped at 3 months if there is a high risk of bleeding.

20 ulting from thrombosis, without an increased risk of bleeding.

21 events but was associated with an increased risk of bleeding.

22 atients needing triple therapy increases the risk of bleeding.

23 zed ratio profile correlated poorly with the risk of bleeding.

24 ular events were accompanied by an increased risk of bleeding.

25 the polymorphism was associated with a lower risk of bleeding.

26 Rivaroxaban was associated with an increased risk of bleeding.

27 therapy can be associated with an increased risk of bleeding.

28 0.05 vs control each) without increasing the risk of bleeding.

29 92; P=0.02) was associated with an increased risk of bleeding.

30 ith concurrent bleeding or those with a high risk of bleeding.

31 but not continuing AC carries a significant risk of bleeding.

32 nd aspirin were associated with an increased risk of bleeding.

33 oncerns because of their potential increased risk of bleeding.

34 t cohort with a CHADS(2) score=2 and a lower-risk of bleeding.

35 ogenous antithrombin itself may increase the risk of bleeding.

36 ternative anticoagulants and their attendant risk of bleeding.

37 nting postoperative nausea without increased risk of bleeding.

38 ociated with a moderate relative increase in risk of bleeding.

39 embolic complications without increasing the risk of bleeding.

40 llows effective anticoagulation with minimal risk of bleeding.

41 ulants has been associated with an increased risk of bleeding.

42 schemic complications without increasing the risk of bleeding.

43 l procedures are associated with significant risk of bleeding.

44 hat may reduce these events but also poses a risk of bleeding.

45 is associated with a significant increase in risk of bleeding.

46 res are performed percutaneously and carry a risk of bleeding.

47 ctivities retain efficacy while reducing the risk of bleeding.

48 haemic events but substantially increase the risk of bleeding.

49 no evidence that FFP transfusion alters the risk of bleeding.

50 a newer antiplatelet agent, can increase the risk of bleeding.

51 et all effective therapies also increase the risk of bleeding.

52 psis and may be associated with an increased risk of bleeding.

53 tor use must be weighed against an increased risk of bleeding.

54 rior cardiac surgery, along with a decreased risk of bleeding.

55 %, but that enoxaparin nearly quadrupled the risk of bleeding.

56 rategy must be balanced against an increased risk of bleeding.

57 rove coronary patency without increasing the risk of bleeding.

58 th streptokinase, but there was an increased risk of bleeding.

59 eir narrow therapeutic window and associated risk of bleeding.

60 r acute coronary syndrome but with increased risk of bleeding.

61 ascular disease (ASCVD) risk but not at high risk of bleeding.

62 e risk of recurrent VTE while minimizing the risk of bleeding.

63 prove outcomes and may actually increase the risk of bleeding.

64 ally focused on parenchymal injuries and the risk of bleeding.

65 of patients with NS in situations involving risk of bleeding.

66 l fibrillation because of concerns about the risk of bleeding.

67 achieving FVIII activity >=50% abolished the risk of bleeding.

68 prevent and treat thrombosis with a minimal risk of bleeding.

69 ere with hemostasis, leading to an increased risk of bleeding.

70 e (although not mortality), and an increased risk of bleeding.

71 ng cirrhotic patients, most of which were at risk of bleeding.

72 hemoclips after polyp resection reduces the risk of bleeding.

73 death, MI, and stroke without increasing the risk of bleeding.

74 aspect defined a new HCA subgroup at a high risk of bleeding.

75 inhibition and with an acceptable associated risk of bleeding.

76 th atrial fibrillation (AF) but increase the risk of bleeding.

77 are-metal stent (BMS) for patients with high risk of bleeding.

78 rial fibrillation, including those with high risk of bleeding.

79 hey inhibit arterial thrombosis with limited risk of bleeding.

80 though caution is needed in patients at high risk of bleeding.

81 associated with improved outcomes or greater risk of bleeding.

82 k of thrombosis and stroke but increases the risk of bleeding.

83 terpatient dose-response variability and the risks of bleeding.

84 apy (DAPT), yet this treatment leads to high risks of bleeding.

85 rdless of indication) with standard care for risk of bleeding (19 trials on GIB).

86 associated with a transient increase in the risk of bleeding (30.6% of bleed windows vs 24.8% of fir

87 In contrast, the risk of Bleeding Academic Research Consortium type 3 or

88 of ticagrelor was associated with a similar risk of bleeding according to the UDPB and E-CABG bleedi

89 n was associated with a dramatically reduced risk of bleeding across all categories of renal dysfunct

90 cohort of patients was associated with lower risk of bleeding (adjusted odds ratio, 0.51; 95% confide

91 The risk of bleeding after percutaneous coronary interventio

92 atory drugs (NSAIDs) was not associated with risk of bleeding after polypectomy (OR=2.82, 95% C.I, 0.

93 enous thromboembolism unless there is a high risk of bleeding, although more data and better biomarke

94 Tranexamic acid reduces the risk of bleeding among patients undergoing cardiac surge

95 Dasatinib is associated with increased risk of bleeding among patients with chronic myeloid leu

96 g Board because of a significantly increased risk of bleeding among the participants receiving aspiri

97 41 cases: 324 procedures (60%) with standard risk of bleeding and 217 procedures (40%) with increased

98 pulation, characterized by both an increased risk of bleeding and a hypercoagulability state, as seen

99 g negative correlation between the predicted risk of bleeding and actual use of TRA in STEMI.

100 institution is associated with an increased risk of bleeding and adverse events but a trend toward l

101 er TIPS placement is associated with reduced risk of bleeding and ascites.

102 aft biopsies may be accompanied by a greater risk of bleeding and bowel injury, although no standardi

103 ecurrence, and secondarily influenced by the risk of bleeding and by patient preference.

104 ergoing surgical procedures, given increased risk of bleeding and cardiovascular and cerebrovascular

105 An increased risk of bleeding and cardiovascular events was evident w

106 patients with MI was associated with higher risk of bleeding and death compared with clopidogrel.

107 nt stroke and did significantly increase the risk of bleeding and death.

108 ch as for cirrhosis is associated with a low risk of bleeding and death.

109 use of NSAIDs was associated with increased risk of bleeding and excess thrombotic events, even afte

110 s, their efficacy is limited by a heightened risk of bleeding and failure to affect vascular remodeli

111 KA, apixaban had either a lower or a similar risk of bleeding and ischemic outcomes from randomizatio

112 We investigated the risk of bleeding and major cardiovascular outcomes in pa

113 Lower predicted risk of bleeding and mortality among SAFE-PCI trial pati

114 as associated with a significantly increased risk of bleeding and probably would not result in a redu

115 Knowledge about risk of bleeding and short-term thrombotic risk resides

116 d with lower risk of reoperation but greater risk of bleeding and stroke.

117 ospective GTH-AH 01/2010 study to assess the risk of bleeding and the efficacy of hemostatic therapy.

118 g negative association between the predicted risk of bleeding and the use of TRA (P<0.001).

119 Strategies to reduce the daily risk of bleeding and thrombosis, and different threshold

120 ts admitted to the hospital are at increased risk of bleeding and thrombosis.

121 The risk of bleeding and thrombotic events during LVAD suppo

122 Minimizing the risk of bleeding and trauma to the kidney are important

123 sradial PCI (TRI) is associated with reduced risk of bleeding and vascular complications, as compared

124 nary intervention is associated with reduced risk of bleeding and vascular complications.

125 te anticoagulation puts them at considerable risk of bleeding and, with some anticoagulants, fetotoxi

126 coagulant (DOAC), and vice versa, and 30-day risks of bleeding and arterial thromboembolism in patien

127 ct on transplantation surgical complexity vs risks of bleeding and falls.

128 er in the non-ICARD-certified group, but the risks of bleeding and vascular complications and the com

129 atological or oncological reasons who are at risk of bleeding), and chronic transfusion-dependent ane

130 romboprophylaxis because of rapid clearance, risk of bleeding, and central nervous system (CNS) toxic

131 agulation, an antiphospholipid antibody, low risk of bleeding, and patient preference favor indefinit

132 t) and hemophilia B (F-IX deficient)) with a risk of bleeding, and thus might be potentially used in

133 cardiovascular disease clearly outweigh the risks of bleeding, and low-dose aspirin is uniformly rec

134 The risk of bleeding appeared to differ according to smoking

135 e protection; a level beyond which increased risk of bleeding arises.

136 activity does not seem to correlate with the risk of bleeding as suggested from previous studies.

137 tion for ACT, there was a linear increase in risk of bleeding as the ACT approached 365 seconds (P=0.

138 rity of illness on the risk of death and the risk of bleeding associated with drotrecogin alfa (activ

139 ations in era II, and there was no increased risk of bleeding associated with the use of tPA.

140 The main disadvantage of these drugs is the risk of bleeding associated with their use.

141 hese oral agents is limited by the increased risk of bleeding associated with their use.

142 The increased risk of bleeding associated with vitamin K antagonist (V

143 All patients had a greatly increased risk of bleeding at platelet counts of </=5 x 10(9)/L (o

144 of ischemia significantly exceeded the daily risk of bleeding beyond 30 days, supporting the use of i

145 ng medication use was associated with higher risk of bleeding but not stroke.

146 Critically ill patients who have a high risk of bleeding but require prolonged intermittent dial

147 with mild thrombocytopenia and an increased risk of bleeding, but its biological effect on megakaryo

148 r activity <10 U/dL were associated with the risk of bleeding, but only a BS >10 remained highly asso

149 losure of mucosal defects in patients with a risk of bleeding can be a challenge, but also reduces de

150 n are effective but are linked with a higher risk of bleeding compared with low-molecular-weight hepa

151 d regimen tended to be associated with lower risk of bleeding compared with other regimens (RR 0.79 [

152 been preliminarily associated with increased risk of bleeding compared with single antiplatelet thera

153 thromboembolism in adults, and has a reduced risk of bleeding compared with standard anticoagulants.

154 thrombotic therapy, is known to increase the risk of bleeding compared with the use of OAC or DAPT al

155 imilar effects on VTE recurrence and a lower risk of bleeding compared with warfarin for the treatmen

156 , dabigatran use was associated with a lower risk of bleeding compared with warfarin in men (P for in

157 igher mortality (P=0.002) and a 47.2% higher risk of bleeding complications (P=0.019).

158 ing surgical revascularization have a higher risk of bleeding complications and transfusion requireme

159 lar coagulation monitoring, but the inherent risk of bleeding complications associated with blocking

160 rocedural heparin significantly increase the risk of bleeding complications at the time of pacemaker

161 to baseline bleeding risk; those at highest risk of bleeding complications gained the greatest benef

162 Anemia increases risk of bleeding complications in the critically ill.

163 An increased risk of bleeding complications was not observed.

164 lasminogen activators uniformly increase the risk of bleeding complications, especially intracranial

165 f decision rules to identify patients at low risk of bleeding complications, in whom long-term antico

166 uture cardiovascular events as well as their risk of bleeding complications, patients may benefit fro

167 ntithrombotic strategy associated with a low risk of bleeding complications.

168 nts may be associated with unacceptably high risk of bleeding complications.

169 antiplatelet therapy without increasing the risk of bleeding complications.

170 ovenous hemodialysis (CVVHD) to minimize the risk of bleeding complications.

171 arin therapy and are potentially at a higher risk of bleeding complications.

172 Current data suggest that the increased risk of bleeding does not vary according to likelihood o

173 sepsis patients who are already at increased risk of bleeding due to a consumption coagulopathy.

174 otentially harmful side effects, such as the risk of bleeding due to heparin's anticoagulant activity

175 hrombus formation is limited by an increased risk of bleeding due to lysis of hemostatic clots that p

176 nerate recombinant APC variants with reduced risk of bleeding due to reduced anticoagulant activity,

177 ith tirofiban, but no unexpected incremental risk of bleeding due to tirofiban was observed among low

178 The risk of bleeding during antithrombotic therapy in patien

179 th von Willebrand disease, have an increased risk of bleeding during pregnancy and delivery.

180 Patients with immune thrombocytopenia are at risk of bleeding during surgery, and intravenous immunog

181 Moreover, the increased risk of bleeding episodes with clopidogrel and aspirin i

182 et agents has been associated with increased risk of bleeding (especially among the elderly and patie

183 reductions in heparin dosing may reduce the risk of bleeding even further.

184 cutaneous coronary intervention had a higher risk of bleeding events than their white counterparts.

185 lation has been associated with an increased risk of bleeding events, and despite the improvements li

186 prevented excess drug concentration and the risk of bleeding events.

187 conditional logistic regression, we compared risks of bleeding events at 1-month postdischarge betwee

188 The relative risk of bleeding for each BAS compared with no BAS was d

189 therapy with available agents outweighs the risk of bleeding for individual patients.

190 ny BAS was associated with a similarly lower risk of bleeding for men and women; however, the absolut

191 A patient's individual risk of bleeding from antithrombotic therapy should be a

192 c anomaly or variant that could increase the risk of bleeding from microelectrode mapping.

193 ary disease warranting DES but have a higher risk of bleeding from prolonged dual antiplatelet therap

194 ADVICE 8: Endoscopists should understand the risk of bleeding from therapeutic endoscopic interventio

195 progressive disease; and in patients at high risk of bleeding, full-dose LMWH for 7 days followed by

196 ABC-bleeding scores predicting a high 1-year risk of bleeding (>2%) derived greater benefit from trea

197 , patients treated with GC care had a higher risk of bleeding hospitalization (hazard ratio=1.21; P=0

198 0.76-0.96]) lower risk of death, 32% higher risk of bleeding (HR, 1.32 [95% CI, 1.18-1.47]), but low

199 ttenuates the anticoagulant-related lifetime risk of bleeding, implantation is associated with upfron

200 GPI use was associated with increased risk of bleeding in both treatment arms.

201 th, MI, and ischemic stroke without a higher risk of bleeding in consecutive acute MI patients with a

202 whether this benefit outweighs the increased risk of bleeding in elderly patients is unknown.

203 f sorafenib was associated with an increased risk of bleeding in HCC, this was primarily for lower-gr

204 lthough chronic kidney disease increases the risk of bleeding in nonoperative settings, the risk of p

205 Because of the substantial risk of bleeding in patients age > or =75 years, the num

206 Aspirin poses a risk of bleeding in patients undergoing surgery, but it

207 rction (NSTEMI) is associated with increased risk of bleeding in patients who undergo early CABG.

208 ults - tests that are not designed to assess risk of bleeding in patients without a history of bleedi

209 When comparing the risk of bleeding in single-arm phase 2 studies evaluatin

210 nts (66.9%) with a proximal large polyp, the risk of bleeding in the clip group was 3.3% and in the c

211 ile examining novel approaches to reduce the risk of bleeding in this rapidly expanding patient popul

212 latelet requirement and did not increase the risk of bleeding in thrombocytopenic neonates.

213 continue about prolonged ischemic times and risk of bleeding in various MIS settings.

214 Excess dosing was associated with increased risk of bleeding in women (OR 1.72, 95% CI 1.30 to 2.28)

215 Aspirin treatment increased the risk of bleeding in women (OR, 1.68; 95% CI, 1.13-2.52;

216 scular events can be offset by the increased risk of bleeding, including intracranial and gastrointes

217 all regimens that included VKA, whereas the risk of bleeding increased when aspirin (hazard ratio, 1

218 For warfarin-treated patients, the risk of bleeding increases as the INR rises, particularl

219 pe of therapy is no longer effective and the risk of bleeding increases.

220 Whether the underlying risk of bleeding influences the associations between pat

221 istration was associated with an increase in risk of bleeding, irrespective of baseline INR.

222 High risk of bleeding is immediately evident with TT after my

223 coronary events or thromboembolism, whereas risk of bleeding is increased significantly.

224 With attention to heparin dose the risk of bleeding is not a major concern with these agent

225 g as a function of a patient's preprocedural risk of bleeding is unknown.

226 tients at high risk for stroke and increased risk of bleeding, LAAC was noninferior to DOAC in preven

227 zelle Bare Metal Stent in Patients With High Risk of Bleeding [LEADERS FREE]; NCT01623180).

228 characteristics associated with an increased risk of bleeding, lower-risk infarction, less certain di

229 icient anticoagulant properties with reduced risk of bleeding may be possible through inhibition of f

230 Furthermore, the risk of bleeding may not be altered by the use of acid s

231 -6 days/wk) were associated with the highest risk of bleeding (multivariable HR, 2.32; 95% CI, 1.34-4

232 The risk of bleeding (n = 1202 events) was not significantly

233 ve participants <70 years of age not at high risk of bleeding (n=3540).

234 was associated with an increased short-term risk of bleeding (odds ratio = 1.42; 95% confidence inte

235 8 vs. 74 min; p < 0.0001) but lower adjusted risk of bleeding (odds ratio [OR]: 0.62; 95% CI: 0.53 to

236 e risk of recurrent VTE off anticoagulation, risk of bleeding on anticoagulation, case fatality or al

237 s > or = 0.26 (base case 0.15), the relative risk of bleeding on BB is > or = 0.69 (base case 0.58),

238 The ICUR favored EVL unless the relative risk of bleeding on BB is < 0.46, the relative risk of b

239 ransplant recipients, including those at low risk of bleeding or high risk of thromboembolic complica

240 ransplants might be prevented by an elevated risk of bleeding or limited access to the allograft.

241 t significantly associated with an increased risk of bleeding or mortality.

242 ll tolerated, with no evidence for increased risk of bleeding or serious adverse events.

243 l dabigatran use significantly increases the risk of bleeding or thromboembolic complications compare

244 tio (INR) are routinely tested to assess the risk of bleeding or thrombosis and to monitor response t

245 rug-eluting stents (DES) in patients at high risk of bleeding or thrombosis has not been prospectivel

246 elationship between plasma VWF level and the risk of bleeding or thrombosis.

247 No excess risks of bleeding or other serious adverse events were o

248 bleeding should only be considered when the risk of bleeding outweighs the risk of thrombotic compli

249 Pediatric subjects were at higher risk of bleeding over a wide range of platelet counts, i

250 vs. 11% vs. 6%, p = 0.006), and had a higher risk of bleeding (p = 0001).

251 s with adjunctive GPIIb/IIIa inhibition, the risk of bleeding, particularly from the femoral vascular

252 administer during a code, and the increased risks of bleeding, particularly with ongoing chest compr

253 The risk of bleeding peaks early after HMII implantation.

254 ogical thromboprophylaxis but with a reduced risk of bleeding (relative risk, 0.41; 95% CI, 0.25-0.65

255 are currently identified by default, a high risk of bleeding remains a clinical issue.

256 Optimal thromboprophylaxis for patients at risk of bleeding remains uncertain.

257 ng was associated with an increased adjusted risk of bleeding requiring a return to the operating roo

258 I): 0.86 to 1.16]) but significantly greater risk of bleeding requiring hospitalization (adjusted HR:

259 Risk of bleeding (requiring hospitalization) or a compos

260 RR: 0.52, 95% CI: 0.35 to 0.76) but a higher risk of bleeding (RR: 2.80, 95% CI: 2.18 to 3.60).

261 ems to be limited to men, whereas the higher risk of bleeding seems to be limited to women.

262 or thromboembolic complications and a higher risk of bleeding than an antiplatelet-based strategy.

263 over clopidogrel alone and carries a greater risk of bleeding than clopidogrel alone.

264 ath or thrombotic complications nor a higher risk of bleeding than that with placebo.

265 or thromboembolic complications and a higher risk of bleeding than the antiplatelet-based strategy.

266 tranexamic acid was associated with a lower risk of bleeding than was placebo, without a higher risk

267 CrI, 0.15-0.62) were associated with a lower risk of bleeding than was the LMWH-vitamin K antagonist

268 e convenient and are thought to have a lower risk of bleeding; they are less suitable if there is a h

269 Aspirin significantly increased the risk of bleeding to a similar degree among women and men

270 atients) were categorized according to their risk of bleeding using the PARIS bleeding risk score.

271 follow-up was 6.4-fold higher, the relative risk of bleeding was 3.2-fold higher, and the relative r

272 The risk of bleeding was also increased among patients who h

273 as an outpatient procedure, (2) whether the risk of bleeding was associated with either thrombocytop

274 The incremental risk of bleeding was greatest in the first year and simi

275 The risk of bleeding was greatest the first year.

276 In contrast, in children under 18, the risk of bleeding was higher in all treatment groups than

277 The overall risk of bleeding was lower with ximelagatran than warfar

278 The greatest risk of bleeding was noted within 2 weeks post-implantat

279 No increased risk of bleeding was seen in this setup.

280 the patient with acute renal failure at high risk of bleeding, we have proposed regional heparinizati

281 t, as compared with clopidogrel, and similar risks of bleeding were observed.

282 cedural heparin (n = 154) markedly increased risk of bleeding when compared with holding warfarin unt

283 tinued P2Y(12) inhibitor monotherapy reduces risk of bleeding when stopped 1 to 3 months after PCI.

284 oagulation is often chosen if there is a low risk of bleeding, whereas anticoagulation is usually sto

285 There may be a slightly higher risk of bleeding, which may be related to the lack of br

286 d to inadequate clot formation and increased risk of bleeding, while thrombocythemia (platelet counts

287 lar bare-metal stent in patients with a high risk of bleeding who underwent PCI.

288 sk of bleeding on BB is < 0.46, the relative risk of bleeding with EVL is > 0.46, or the time horizon

289 = 0.69 (base case 0.58), or if the relative risk of bleeding with EVL is < 0.27 (base case 0.35).

290 In CHARISMA, there was an increased risk of bleeding with long-term clopidogrel.

291 sted Cox regression analysis found increased risk of bleeding with NSAID treatment compared with no N

292 a inhibitor does not accentuate the relative risk of bleeding with prasugrel as compared with clopido

293 ior to VKAs with regard to efficacy, but the risk of bleeding with TSOACs remains controversial.

294 s can identify patients who are at increased risk of bleeding with warfarin and, consequently, those

295 mation of the benefit and underestimation of risk of bleeding with warfarin in clinical trials.

296 3%, 0-32.6; ptrend<0.0001) and had increased risks of bleeding with warfarin (sensitive responders ha

297 across the entire spectrum of preprocedural risk of bleeding, with or without exposure to IIb/IIIa i

298 tion and stent thrombosis, but decreases the risk of bleeding, with the magnitude of the reduction de

299 some direct oral anticoagulants reduces the risk of bleeding without compromising efficacy, (2) the

300 acetylsalicylic acid alone but increases the risk of bleeding without reducing mortality.